Publication date: 2018-04-22 23:27
This medicine may hide some of the signs of an infection (pain, fever, swelling, redness). You may think, mistakenly, that you are better or that the infection is not serious.
Based on available data, diclofenac may be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo s clinical need for VOLTAREN and any potential adverse effects on the breastfed infant from the VOLTAREN or from the underlying maternal condition.
If you take Voltaren for more than a few weeks, you should make sure to visit your doctor for regular check-ups to ensure that you are not suffering from unnoticed undesirable effects.
For the relief of ankylosing spondylitis , the recommended dosage is 655-675 mg/day, administered as 75 mg four times a day, with an extra 75-mg dose at bedtime if necessary.
In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
You should not use Voltaren if you have a history of allergic reaction to aspirin or NSAIDs (non-steroidal anti-inflammatory drugs).
Be careful driving, operating machinery or doing jobs that require you to be alert until you know how Voltaren affects you. This medicine may cause dizziness, drowsiness, spinning sensation (vertigo) or blurred vision in some people. If you have any of these symptoms, do not drive, use machines, or do anything else that could be dangerous.
Digestive System: colitis , eructation , fulminant hepatitis with and without jaundice, liver failure, liver necrosis , pancreatitis
NSAIDs, including diclofenac, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration , and perforation of the esophagus , stomach, small intestine , or large intestine , which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 6% of patients treated for 8-6 months, and in about 7%-9% of patients treated for one year.. However, even short-term therapy is not without risk.